Download This Paper
Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
FASE-CPHG Study: A Panoramic Snapshot of Severe Asthma in French Non-Academic Hospitals
23 Pages Posted: 16 Jan 2019
More...Abstract
Background: Real-world data describing management of patients with severe asthma are limited. To address this issue, we conducted FASE-CPHG, a descriptive, multicentric, and observational cross-sectional study.
Methods: French pulmonologists from nonacademic hospitals completed questionnaires on patient characteristics and ongoing asthma treatment for severe asthmatic patients observed during the inclusion period. We also collected data from patients via self-assessment questionnaires.
Findings: A total of 104 physicians recruited 1502 patients within one year. The mean age of the 1465 patients analyzed was 54·4 ± 16·1 years. Severe asthmatic patients were more frequently female (62,6%), with a history of atopy (65%). Most patients remained poorly controlled or uncontrolled, with an important difference between physicians’ opinion and the GINA criteria (62,6% vs. 96% of patients). Most common comorbidities included ear, nose, and throat diseases (59% of cases); anxiety (39·5%); and gastro-esophageal reflux diseases (39·1%). Allergic sensitization tests and/or blood eosinophil count evaluation, and spirometry were performed in 92·1% and 98·2% of patients, respectively. The mean eosinophil count and total serum IgE were 437 mm3 and 546 UI/L, respectively. In addition to high doses of inhaled corticosteroids plus long-acting beta-2 agonists, 52·2% of patients were receiving leukotriene receptor antagonists, 34% anticholinergic drugs, 26·8% anti IgE, and 16·8% oral corticosteroids, while 65% adhered to their treatment.
Interpretation: This study provides insight into the characteristics and management of severe asthma in France and may help improve knowledge on this pathology, which represents a high burden to healthcare.
Funding Statement: ALK, AstraZeneca, Boehringer Ingelheim, GSK, Le Nouveau Souffle.
Declaration of Interests: "None"
Ethics Approval Statement: The study was approved by the local ethics committee (Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le domaine de la Santé) and was conducted according to the French law and guidelines on epidemiological and descriptive studies.
Keywords: severe asthma
Suggested Citation: Suggested Citation